A review of current progress in triple-negative breast cancer therapy
Triple-negative breast cancer (TNBC) is a particularly aggressive subtype known for its extremely high drug resistance, progression, poor prognosis, and lack of clear therapeutic targets. Researchers are aiming to advance TNBC treatment worldwide. In the past 2–3 years, more positive results have em...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2020-11-01
|
| Series: | Open Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/med-2020-0138 |
| _version_ | 1818676740746117120 |
|---|---|
| author | Shen Meiying Pan Huawen Chen Yuxia Xu Yu Hang Yang Weixiong Wu Zhaojun |
| author_facet | Shen Meiying Pan Huawen Chen Yuxia Xu Yu Hang Yang Weixiong Wu Zhaojun |
| author_sort | Shen Meiying |
| collection | DOAJ |
| description | Triple-negative breast cancer (TNBC) is a particularly aggressive subtype known for its extremely high drug resistance, progression, poor prognosis, and lack of clear therapeutic targets. Researchers are aiming to advance TNBC treatment worldwide. In the past 2–3 years, more positive results have emerged in the clinical research on TNBC treatment. Based on the results, several impressive drugs have been approved to benefit patients with TNBC, including the PARP inhibitors olaparib and talazoparib for germline BRCA mutation-associated breast cancer (gBRCAm-BC) and immunotherapy using the checkpoint inhibitor atezolizumab in combination with nab-paclitaxel for programmed cell death-ligand 1-positive (PD-L1+) advanced TNBC. Although neoadjuvant therapy has focused on combinations of systemic agents to optimize pathologically complete response, metastatic TNBC still has a poor prognosis. Innovative multidrug combination systemic therapies based on neoadjuvants and adjuvants have led to significant improvements in outcomes, particularly over the past decade. |
| first_indexed | 2024-12-17T08:48:17Z |
| format | Article |
| id | doaj.art-11adfd2aec4b4f8eb53bc84fcf32ec3d |
| institution | Directory Open Access Journal |
| issn | 2391-5463 |
| language | English |
| last_indexed | 2024-12-17T08:48:17Z |
| publishDate | 2020-11-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Open Medicine |
| spelling | doaj.art-11adfd2aec4b4f8eb53bc84fcf32ec3d2022-12-21T21:56:09ZengDe GruyterOpen Medicine2391-54632020-11-011511143114910.1515/med-2020-0138med-2020-0138A review of current progress in triple-negative breast cancer therapyShen Meiying0Pan Huawen1Chen Yuxia2Xu Yu Hang3Yang Weixiong4Wu Zhaojun5Department of Mammary Gland, Maoming People’s Hospital, Maoming, 525000, ChinaDepartment of Spinal, Maoming People’s Hospital, Maoming, 525000, ChinaDepartment of Mammary Gland, Maoming People’s Hospital, Maoming, 525000, ChinaDepartment of Mammary Gland, Maoming People’s Hospital, Maoming, 525000, ChinaDepartment of Mammary Gland, Maoming People’s Hospital, Maoming, 525000, ChinaDepartment of Ultrasound, Maoming People’s Hospital, Maoming, 525000, ChinaTriple-negative breast cancer (TNBC) is a particularly aggressive subtype known for its extremely high drug resistance, progression, poor prognosis, and lack of clear therapeutic targets. Researchers are aiming to advance TNBC treatment worldwide. In the past 2–3 years, more positive results have emerged in the clinical research on TNBC treatment. Based on the results, several impressive drugs have been approved to benefit patients with TNBC, including the PARP inhibitors olaparib and talazoparib for germline BRCA mutation-associated breast cancer (gBRCAm-BC) and immunotherapy using the checkpoint inhibitor atezolizumab in combination with nab-paclitaxel for programmed cell death-ligand 1-positive (PD-L1+) advanced TNBC. Although neoadjuvant therapy has focused on combinations of systemic agents to optimize pathologically complete response, metastatic TNBC still has a poor prognosis. Innovative multidrug combination systemic therapies based on neoadjuvants and adjuvants have led to significant improvements in outcomes, particularly over the past decade.https://doi.org/10.1515/med-2020-0138triple-negative breast cancerparp inhibitionimmunotherapyadjuvant therapy |
| spellingShingle | Shen Meiying Pan Huawen Chen Yuxia Xu Yu Hang Yang Weixiong Wu Zhaojun A review of current progress in triple-negative breast cancer therapy Open Medicine triple-negative breast cancer parp inhibition immunotherapy adjuvant therapy |
| title | A review of current progress in triple-negative breast cancer therapy |
| title_full | A review of current progress in triple-negative breast cancer therapy |
| title_fullStr | A review of current progress in triple-negative breast cancer therapy |
| title_full_unstemmed | A review of current progress in triple-negative breast cancer therapy |
| title_short | A review of current progress in triple-negative breast cancer therapy |
| title_sort | review of current progress in triple negative breast cancer therapy |
| topic | triple-negative breast cancer parp inhibition immunotherapy adjuvant therapy |
| url | https://doi.org/10.1515/med-2020-0138 |
| work_keys_str_mv | AT shenmeiying areviewofcurrentprogressintriplenegativebreastcancertherapy AT panhuawen areviewofcurrentprogressintriplenegativebreastcancertherapy AT chenyuxia areviewofcurrentprogressintriplenegativebreastcancertherapy AT xuyuhang areviewofcurrentprogressintriplenegativebreastcancertherapy AT yangweixiong areviewofcurrentprogressintriplenegativebreastcancertherapy AT wuzhaojun areviewofcurrentprogressintriplenegativebreastcancertherapy AT shenmeiying reviewofcurrentprogressintriplenegativebreastcancertherapy AT panhuawen reviewofcurrentprogressintriplenegativebreastcancertherapy AT chenyuxia reviewofcurrentprogressintriplenegativebreastcancertherapy AT xuyuhang reviewofcurrentprogressintriplenegativebreastcancertherapy AT yangweixiong reviewofcurrentprogressintriplenegativebreastcancertherapy AT wuzhaojun reviewofcurrentprogressintriplenegativebreastcancertherapy |